Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung Cancer: A Systematic Review

CONCLUSION: Doxil® significantly reduced cellular proliferation in vitro and improved survival in vivo in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC, additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on its activity and effects in humans.PMID:38099532 | DOI:10.2174/0115672018272162231116093143

Source: Current Drug Delivery - December 15, 2023 Category: Drugs & Pharmacology Authors: Pablo Redruello-Guerrero Paula Cordoba Antonio L áinez-Ramos-Bossini Mario Rivera Cristina Mesas Raul Ortiz Jose Prados Gloria Perazzoli Source Type: research